Drugs / OPC-64005
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04244253 | Mar 2020 → Feb 2022 | major depressive disorder | Otsuka Pharmaceutical Co., Ltd. | Completed | Missed primary |
| Phase 2 | NCT03324581 | Nov 2017 → Oct 2018 | attention deficit-hyperactivity disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Completed | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OPC-64005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03324581 ↗ |
| Route | Oral | “orally, once daily (QD)” NCT03324581 ↗ |